UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO of United Therapeutics) exercised 9,500 stock options and sold 9,500 shares of UTHR common stock held via a family trust on 2026-07-28 under a 10b5-1 plan, for total sale proceeds of roughly $5.0 million.

On July 28, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share and acquired an equal number of common shares, then immediately sold all 9,500 resulting shares in multiple open‑market transactions at weighted average prices between approximately $523.15 and $532.49 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. The option exercise, reported as an acquisition, had a gross intrinsic value of roughly $3.7 million based on the sale prices, while the series of sales generated aggregate proceeds of about $5.0 million and reduced the trust’s directly reported holdings in this account from 333,943 to 324,443 shares. After these transactions, Rothblatt continues to hold substantial additional United Therapeutics equity across several family trusts, spouse‑related trusts, and other directly held common shares and options.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000108

Alert Tier

7